Dr. Voorhees on Updated Results of the GRIFFIN Trial in Multiple Myeloma

Video

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

The phase 2 GRIFFIN study evaluated the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (​D-RVd) versus the standard triplet regimen of RVd in patients with transplant-eligible, newly diagnosed multiple myeloma.

Updated results ​of the study, which were presented during the 2020 ASH Annual Meeting ​& Exposition, demonstrated a 42.4% stringent complete response (sCR) rate with D-RVd versus​ 32.0% with RVd at a median follow-up of 13.5 months. Notably, with additional daratumumab/lenalidomide or lenalidomide maintenance therapy, responses deepened and remained higher for the D-RVd group ​versus the RVd group. At a median follow-up of 26.7 months, the sCR rate continued to favor D-RVd versus RVd (63.6% and47.4%​, respectively), Voorhees adds.

Furthermore, minimal residual disease (MRD)–negativity (​defined as 10‑5 threshold per International Myeloma Working Group criteria) rates favored D-RVd versus RVd (62.5% and 27.2%, respectively)​ in the intention-to-treat (ITT) population, as well as among patients who achieved ​a CR or better (76.5% and 42.4%, respectively). MRD negativity (defined as 10‒6) rates also favored D-RVd versus RVd in the ITT population (26.9% and 12.6%, respectively)​, as well as among patients who achieved CR or better (34.6% and18.6%, respectively). Taken collectively, these findings emphasize the importance of sustained MRD negativity, Voorhees concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,